Turing Pharmaceuticals, the drug company that jacked up the price of a drug used by AIDS and cancer patients by more than 5,000%, is facing an antitrust probe by New York Attorney General Eric Schneiderman.
The drug company raised the price of Daraprim, a 62-year old drug no longer under patent protection, to $750 a tablet from $13.50.
The drug’s main use is to treat life-threatening parasitic infections but it is also needed by some infants and patients with AIDS. The price hike sparked howls of protest and the company promised to lower the price but has yet to do so.
The investigation, which was confirmed by Schneiderman’s office, is looking at whether Turing is restricting the distribution of Daraprim to thwart generic competition that would prevent it from maintaining the massive price increase. The office is concerned Turing restricted distribution of the drug specifically so generic drug manufacturers couldn’t get the samples they need to create their own version.
Full content: Human Rights Campaign
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Wilson Sonsini Bolsters Antitrust and Competition Practice with Key Partner Returns
May 8, 2024 by
CPI
EU to Scrutinize Telecom Italia’s Network Sale to KKR
May 8, 2024 by
CPI
Turkey Hits Meta with $37.20 Million Fine Over Data-Sharing Practices
May 8, 2024 by
CPI
Google Seeks Dismissal of UK Suit Over Alleged Anti-Competitive Practices
May 8, 2024 by
CPI
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI